Joseph K. Belanoff - Feb 28, 2025 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Chief Executive Officer, Director
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Joseph K. Belanoff.
Stock symbol
CORT
Transactions as of
Feb 28, 2025
Transactions value $
-$178,098
Form type
4
Date filed
3/4/2025, 07:44 PM
Previous filing
Feb 14, 2025
Next filing
Mar 26, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Sale -$178K -2.92K -0.1% $60.91 3.02M Mar 3, 2025 Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Award $0 +350K $0.00 350K Feb 28, 2025 Common Stock 350K $60.58 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
F2 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $60.83 to $61.045 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3 Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
F4 Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.